Fibrinogen and future cardiovascular disease in people with diabetes: Aetiological associations and risk prediction using individual participant data from nine community-based prospective cohort studies

Diabetes and Vascular Disease Research

Volumn 10, Issue 2, 2013, Pages 143-151

  Kengne, Andre P ^a,b,c   Czernichow, Sebastien ^d,e   Stamatakis, Emmanuel ^f   Hamer, Mark ^f   Batty, G David ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^d Genetics Division Ambroise Paré Hospital AP HP   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cardiovascular diseases; diabetes mellitus; Fibrinogen; mortality; prognosis; risk factors

Indexed keywords

FIBRINOGEN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMMUNITY CARE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FIBRINOGEN BLOOD LEVEL; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; UNITED KINGDOM;

ADULT; AGED; AREA UNDER CURVE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FIBRINOGEN; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84874051094     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112451588     Document Type: Article

References (34)

1. Kamath S, Lip GY. Fibrinogen: Biochemistry, epidemiology and determinants. QJM. 2003 ; 96: 711-729
2. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA. 2005 ; 294: 1799-1809
3. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA. 1998 ; 279: 1477-1482
4. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med. 1993 ; 118: 956-963
5. Ridker PM, Brown NJ, Vaughan DE, et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004 ; 109: IV6 - IV19
6. Kaptoge S, White IR, Thompson SG, et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: Individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol. 2007 ; 166: 867-879
7. Kizer JR, Krauser DG, Rodeheffer RJ, et al. Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study). Am J Cardiol. 2009 ; 104: 247-253
8. Bruno G, Merletti F, Biggeri A, et al. Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: The Casale Monferrato Study. Diabetologia. 2005 ; 48: 427-434
9. Scottish Health Survey Publications. The Scottish Government Statistics.Available at: http://www.scotland.gov.uk/Topics/Statistics/Browse/ Health/scottish-health-survey/Publications (accessed 1 July 2011)
10. Cardiovascular disease. London: The Stationery Office ; 1999 :
11. Le Gallais D, Prefaut C, Mercier J, et al. Sickle cell trait as a limiting factor for high-level performance in a semi-marathon. Int J Sports Med. 1994 ; 15: 399-402
12. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995 ; 57: 289-300
13. Lin D, Wei L, Yin Z. Checking the Cox model with cumulative sums of Martingales-based residuals. Biometrika. 2003 ; 80: 557-572
14. Easton DF, Peto J, Babiker AG. Floating absolute risk: An alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med. 1991 ; 10: 1025-1035
15. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 1988 ; 44: 837-845
16. Pencina MJ, D'Agostino RB, D'Agostino RB, et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med. 2008 ; 27: 157-172
17. Collett D Modelling survival data in medical research. 2 nd ed.New York: Chapman & Hall/CRC, 2003, p.391. New York: Chapman & Hall/CRC ; 2003: 391.
18. Hosmer DW, Hosmer T, Le Cessie S, et al. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 1997 ; 16: 965-980
19. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991 ; 121: 293-298
20. Engstrom G, Stavenow L, Hedblad B, et al. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: A population-based study. Diabetes. 2003 ; 52: 442-447
21. Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes. 2002 ; 51: 1157-1165
22. Bartlett JW, De Stavola BL, Meade TW. Assessing the contribution of fibrinogen in predicting risk of death in men with peripheral arterial disease. J Thromb Haemost. 2009 ; 7: 270-276
23. Kengne AP, Patel A, Colagiuri S, et al. The Framingham and UKPDS risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: The Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia. 2010 ; 53: 821-831
24. De Maat MP. Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann N Y Acad Sci. 2001 ; 936: 509-521
25. Circulation. 2000 ; 102: 21-27
26. Smith GD, Harbord R, Milton J, et al. Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol. 2005 ; 25: 2228-2233
27. Keavney B, Danesh J, Parish S, et al. Fibrinogen and coronary heart disease: Test of causality by 'Mendelian randomization'. Int J Epidemiol. 2006 ; 35: 935-943
28. Meade TW, Humphries SE, De Stavola BL, et al. Commentary: Fibrinogen and coronary heart disease - test of causality by 'Mendelian' randomization by Keavney. Int J Epidemiol. 2006 ; 35: 944-947
29. Mannila MN, Eriksson P, Lundman P, et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost. 2005 ; 93: 570-577
30. Ken-Dror G, Humphries SE, Kumari M, et al. A genetic instrument for Mendelian randomization of fibrinogen. Eur J Epidemiol. 2012 ; 27: 267-279
31. Moons KG, Altman DG, Vergouwe Y, et al. Prognosis and prognostic research: Application and impact of prognostic models in clinical practice. BMJ. 2009 ; 338: b606
32. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006 ; 355: 2631-2639
33. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008 ; 358: 2107-2116
34. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: The atherosclerosis risk in communities study. Arch Intern Med. 2006 ; 166: 1368-1373